"MSB had EAP to treat 50 covid patients. If they would have treated 24 and still got 83% survival we would not be at $3.04. The company must have been very confident to stop at 12".
It is a very good point you make Lopez. I never understood why they didn't continue the EAP anyway. Not exactly a dearth of patients for the trial with 1,000 deaths a day in the US. I wish they'd continued the EAP to 24. Perhaps with 20/24 in the Bayesian prior and a quicker NIH/Mt Sinai recrutiment we'd be stopped already for statistical efficacy.
Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-380
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |